289 related articles for article (PubMed ID: 37869947)
21. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
[TBL] [Abstract][Full Text] [Related]
22. IgE and eosinophils as therapeutic targets in asthma.
Patel TR; Sur S
Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
[TBL] [Abstract][Full Text] [Related]
23. Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: A real-world study.
Bajpai S; Marino MJ; Rank MA; Donaldson AM; O'Brien EK; Lal D
Int Forum Allergy Rhinol; 2021 Aug; 11(8):1152-1161. PubMed ID: 33527730
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Dermatitis During Pregnancy and Lactation.
L Ramos C; Namazy J
Immunol Allergy Clin North Am; 2023 Feb; 43(1):187-197. PubMed ID: 36411004
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps.
Koski RR; Hill L; Taavola K
J Pharm Technol; 2022 Oct; 38(5):289-296. PubMed ID: 36046351
[No Abstract] [Full Text] [Related]
26. The Role of Biologics in the Treatment of Nasal Polyps.
Franzese CB
Immunol Allergy Clin North Am; 2020 May; 40(2):295-302. PubMed ID: 32278452
[TBL] [Abstract][Full Text] [Related]
27. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti-IL-5 Biologics: A Real-Life Study.
Barroso B; Valverde-Monge M; Alobid I; Olaguibel JM; Rial MJ; Quirce S; Arismendi E; Barranco P; Betancor D; Bobolea I; Cárdaba B; Cruz Carmona MJ; Curto E; Domínguez-Ortega J; González-Barcala FJ; Martínez-Rivera C; Mahíllo-Fernández I; Muñoz X; Picado C; Plaza V; Rodrigo Muñoz JM; Soto-Retes L; Valero A; Del Pozo V; Mullol J; Sastre J
J Investig Allergol Clin Immunol; 2023 Feb; 33(1):37-44. PubMed ID: 35416154
[TBL] [Abstract][Full Text] [Related]
28. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of refractory asthma with antibodies].
Lommatzsch M
Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629
[TBL] [Abstract][Full Text] [Related]
30. Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.
Domingo C
Drugs; 2017 Oct; 77(16):1769-1787. PubMed ID: 28948572
[TBL] [Abstract][Full Text] [Related]
31. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
[TBL] [Abstract][Full Text] [Related]
32. Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma.
Chan R; RuiWen Kuo C; Lipworth B
J Allergy Clin Immunol Pract; 2020; 8(10):3363-3370. PubMed ID: 32673880
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma.
Weinstein SF; Katial R; Jayawardena S; Pirozzi G; Staudinger H; Eckert L; Joish VN; Amin N; Maroni J; Rowe P; Graham NMH; Teper A
J Allergy Clin Immunol; 2018 Jul; 142(1):171-177.e1. PubMed ID: 29355679
[TBL] [Abstract][Full Text] [Related]
34. Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis.
Tsabouri S; Ntritsos G; Koskeridis F; Evangelou E; Olsson P; Kostikas K
Rhinology; 2021 Dec; 59(6):501-510. PubMed ID: 34714895
[TBL] [Abstract][Full Text] [Related]
35. [Biologicals in the Treatment of Bronchial Asthma].
Haasler I; Taube C
Pneumologie; 2017 Oct; 71(10):684-698. PubMed ID: 29017221
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Monoclonal Antibodies for Treatment of Uncontrolled Eosinophilic Asthma.
Koski RR; Grzegorczyk KM
J Pharm Pract; 2020 Aug; 33(4):513-522. PubMed ID: 31046541
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Rocha C; Beltran J; Song Y; Posso M; Solà I; Alonso-Coello P; Akdis C; Akdis M; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Martín IH; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Quirce S; Sastre J; Shamji M; Schwarze J; Canelo-Aybar C; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1043-1057. PubMed ID: 32064642
[TBL] [Abstract][Full Text] [Related]
38. Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals.
Akenroye AT; Heyward J; Keet C; Alexander GC
J Allergy Clin Immunol Pract; 2021 Nov; 9(11):3969-3976. PubMed ID: 33556592
[TBL] [Abstract][Full Text] [Related]
39. A risk of serious anaphylatic reactions to asthma biologics: a pharmacovigilance study based on a global real-world database.
Park S; Kim Y; Lee GH; Choi SA
Sci Rep; 2023 Oct; 13(1):17607. PubMed ID: 37848636
[TBL] [Abstract][Full Text] [Related]
40. Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis: A Systematic Review and Meta-analysis.
Rivero A; Liang J
Ann Otol Rhinol Laryngol; 2017 Nov; 126(11):739-747. PubMed ID: 28918644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
